ClinicalTrials.gg
Not yet recruitingNCT07394270Updated Feb 6, 2026

Effect of Add-on L-Arginine Therapy on Heart Failure Patients

A Phase 2 interventional study of L-Arginine Powder and Placebo in Heart Failure, sponsored by German University in Cairo. Not yet recruiting at 1 site in Egypt. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by German University in Cairo · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Heart Failure with a site in Egypt — 16 open to participants now, 21 under way, 2 of them phase 3. Heart Failure · Egypt.

Planned enrollment
3rd of 46
200 · median 68
Started
2026
with 10 others
Phase 2
7 of 63
3 open now
Primary completion
2027-03
later than 17 of 20 live
Registered
52nd of 63
by date

Among the 63 studies in Heart Failure with a site in Egypt, this one is the 3rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 17 of the 20 other live ones, and was the 52nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 63 studies in Heart Failure with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Heart Failure with a site in Egypt, or all of them as a file.
02

Study summary

Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
  • Drug repurposing
  • L-Arginine
  • Add-on therapy
  • HFrEF
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with EF \<40%
  • >30 mL/min/1.73 m2
  • Stable patients
  • Capable and willing to provide written consent

Exclusion criteria

Exclusion Criteria:

  • Patients with implantable cardioverter-defibrillator
  • Pregnant or lactating fmeales
  • Patients with a history of sensitivity to L-Arginine or any of the
  • Acute heart failure patients
  • Patients use L-arginine supplementation.
  • Patients with active herpes disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    L-Arginine Arm

    Patients in this arm will be administered 6 gm L-arginine per day

    Drug: L-Arginine Powder

  • Placebo comparator
    Placebo Arm

    Patients in this arm will take 6 gm placebo per day

    Drug: Placebo

Interventions

  • DrugArginineStudies of ArginineArginine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    L-arginine 3 gm sachets are used twice daily

  • DrugPlacebo

    2 sachets of placebo are administered per day

06

What researchers measure

Primary outcomes

  1. Change of Global longitudinal strain value (GLS) of HF patients from the baseline

    Time frame: 6 weeks

Secondary outcomes

  1. Change of heart failure symptoms as determined by NYHA classification from baseline

    Time frame: 6 weeks

  2. Change of the functional abilities (ECG) of the patients as determined by the exercise test from baseline

    Time frame: 6 weeks

  3. Changes in biomarkers of heart failure as determined by the difference in NT-proBNP levels from baseline

    Time frame: 6 weeks

  4. Change in quality of life between 2 groups as determined by Minnesota Living with Heart Failure questionnaire

    Time frame: 6 weeks

  5. Safety profile of the L-Arginine as determined by the change in the mean arterial pressure (MAP) between the 2 groups

    Time frame: 6 weeks

  6. Change in biomarkers of endothelial dysfunction as determined by the difference in levels of endothelin-1

    Time frame: 6 weeks

  7. Change in biomarkers of endothelial dysfunction as determined by the difference in levels of Asymmetric dimethylarginine (ADMA)

    Time frame: 6 weeks

  8. Safety profile of the L-Arginine as determined by the change in the heart rate (HR) between the 2 groups

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Mar 2027, 13 months later.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 13 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Feb 6, 2026
StartEst.
Feb 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07394270
Lead sponsor
German University in Cairo
Responsible party
Sara Araby (Msc., German University in Cairo) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Sara Araby, Msc
Contact
sara.araby96@gmail.com
+201008662223
Mohamed Solayman, PhD
Contact
mohamed.solayman@guc.edu.eg
+201005882550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion